Pine Valley Investments’s Corcept Therapeutics CORT Stock Holding History

Pine Valley Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$352K	Buy	+4,049	New	+$244K	0.01%	465

Other funds holding CORT

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Pine Valley Investments's CORT Position: Q2 2026 in Review

Pine Valley Investments opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,049 shares worth $352K. The stake represents 0.01% of the portfolio and ranks #465 among its holdings.

147 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Pine Valley Investments held 4,049 shares of Corcept Therapeutics worth $352K as of Q2 2026.
Corcept Therapeutics was a new Pine Valley Investments position in Q2 2026.
Corcept Therapeutics made up 0.01% of Pine Valley Investments's portfolio in Q2 2026, its #465 holding.
147 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Pine Valley Investments's 13F filing for Q2 2026, filed 24 Jul 2026.